Sunday, 25 August 2013

Fibromyalgia And Nerve Pain

Today's post from (see link below) talks about the connection between Fibromyalgia and small fibre neuropathy. A recent small study has identified neuropathy in many fibromyalgia patients, suggesting that the cause of fibromyalgia may stem from neuropathic conditions. Fibromyalgia, like neuropathy, sometimes defies logic, with no apparent cause and no effective treatments, causing many problems for the sufferers. To be able to prove the causal link between the two conditions may be more of a case of scientists and doctors being able to put two and two together to finally make four because the patient will see little benefit, at least at the moment until effective treatments are developed. It may be of no surprise to fibromyalgia patients that their problems stem from nerve damage but scientifically, it needs to be proved once and for all.

Nerve damage and fibromyalgia
Small study could lead to identification of treatable diseases for some with chronic pain syndrome
By Sue McGreevey, Massachusetts General Hospital Public Affairs July 31, 2013

About half of a small group of patients with fibromyalgia — a common syndrome that causes chronic pain and other symptoms — were found to have damage to nerve fibers in their skin and other evidence of a disease called small-fiber polyneuropathy (SFPN). Unlike fibromyalgia, which has had no known causes and few effective treatments, SFPN has a clear pathology and is known to be caused by specific medical conditions, some of which can be treated and sometimes cured. The study, by researchers at Harvard-affiliated Massachusetts General Hospital (MGH), will appear in the journal Pain and has been released online.

“This provides some of the first objective evidence of a mechanism behind some cases of fibromyalgia, and identifying an underlying cause is the first step towards finding better treatments,” says Anne Louise Oaklander, an associate professor of neurology at Harvard Medical School, director of the Nerve Injury Unit in the MGH Department of Neurology, and corresponding author of the Pain paper.

The term “fibromyalgia” describes a set of symptoms — including chronic widespread pain, increased sensitivity to pressure, and fatigue — that is believed to affect 1 to 5 percent of individuals in Western countries, more frequently women. While a diagnosis of fibromyalgia has been recognized by the National Institutes of Health and the American College of Rheumatology, its biologic basis has remained unknown. Fibromyalgia shares many symptoms with SFPN, a recognized cause of chronic widespread pain for which there are accepted, objective tests.

Designed to investigate possible connections between the two conditions, the current study enrolled 27 adult patients with fibromyalgia diagnoses and 30 healthy volunteers. Participants went through a battery of tests used to diagnose SFPN, including assessments of neuropathy based on a physical examination and responses to a questionnaire, skin biopsies to evaluate the number of nerve fibers in their lower legs, and tests of autonomic functions such as heart rate, blood pressure, and sweating.

The questionnaires, exam assessments, and skin biopsies all found significant levels of neuropathy in the fibromyalgia patients but not in the control group. Of the 27 fibromyalgia patients, 13 had a marked reduction in nerve fiber density, abnormal autonomic function tests, or both, indicating the presence of SFPN. Participants who met criteria for SFPN also underwent blood tests for known causes of the disorder, and while none of them had results suggestive of diabetes, a common cause of SFPN, two were found to have hepatitis C virus infection, which can be successfully treated, and more than half had evidence of some type of immune system dysfunction.

“Until now, there has been no good idea about what causes fibromyalgia, but now we have evidence for some but not all patients. Fibromyalgia is too complex for a ‘one size fits all’ explanation,” says Oaklander. “The next step of independent confirmation of our findings from other laboratories is already happening, and we also need to follow those patients who didn’t meet SFPN criteria to see if we can find other causes. Helping any of these people receive definitive diagnoses and better treatment would be a great accomplishment.”

No comments:

Post a Comment

All comments welcome but advertising your own service or product will unfortunately result in your comment not being published.